Knowledge Mapping of Global Status and Trends for Thromboangiitis Obliterans: A Bibliometrics and Visual Analysis

References

• Olin JW. Thromboangiitis obliterans. Curr Opin Rheumatol. 1994;6(1):44–49. doi:10.1097/00002281-199401000-00008
   PubMedGoogle Scholar
• Buerger L. Landmark publication from the American Journal of the Medical Sciences, ‘Thrombo-angiitis obliterans: a study of the vascular lesions leading to presenile spontaneous gangrene’. 1908. Am J Med Sci. 2009;337(4):274–284. doi:10.1097/MAJ.0b013e31818c8bc9
   PubMed Web of Science ®Google Scholar
• Mills JL. Buerger’s disease in the 21st century: diagnosis, clinical features, and therapy. Semin Vasc Surg. 2003;16(3):179–189. doi:10.1016/s0895-7967(03)00023-1
   PubMedGoogle Scholar
• Choi B, Jang SY, Kim S-K, et al. The incidence, prevalence, and survival rate of thromboangiitis obliterans in Korea: a retrospective population-based study. Cardiovasc Diagn Ther. 2020;10(5):1238–1244. doi:10.21037/cdt-20-582
   PubMed Web of Science ®Google Scholar
• Arkkila PE. Thromboangiitis obliterans (Buerger’s disease). Orphanet J Rare Dis. 2006;1(1):14. doi:10.1186/1750-1172-1-14
   PubMedGoogle Scholar
• Cacione DG, Macedo CR, Do Carmo Novaes F, Baptista-Silva JC. Pharmacological treatment for Buerger’s disease. Cochrane Database Syst Rev. 2020;5(5):Cd011033. doi:10.1002/14651858.CD011033.pub4
   PubMedGoogle Scholar
• Pu H. Endovascular Excimer Laser-Assisted Balloon Angioplasty for Infrapopliteal Arteries in Thromboangiitis Obliterans: a Treatment for Acute-Phase TAO. Front Cardiovasc Med. 2022;9:831340. doi:10.3389/fcvm.2022.831340
   PubMed Web of Science ®Google Scholar
• Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275(5302):964–967. doi:10.1126/science.275.5302.964
   PubMed Web of Science ®Google Scholar
• Tateishi-Yuyama E. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet. 2002;360:427–435. doi:10.1016/s0140-6736(02)09670-8
   PubMed Web of Science ®Google Scholar
• Mills JL, Taylor LM, Porter JM. Buerger’s disease in the modern era. Am J Surg. 1987;154(1):123–129. doi:10.1016/0002-9610(87)90301-1
   PubMed Web of Science ®Google Scholar
• Ohta T, Ishioashi H, Hosaka M, Sugimoto I. Clinical and social consequences of Buerger disease. J Vasc Surg. 2004;39(1):176–180. doi:10.1016/j.jvs.2003.08.006
   PubMed Web of Science ®Google Scholar
• Piazza G, Creager MA. Thromboangiitis obliterans. Circulation. 2010;121(16):1858–1861. doi:10.1161/circulationaha.110.942383
   PubMed Web of Science ®Google Scholar
• Olin JW, Young JR, Graor RA, Ruschhaupt WF, Bartholomew JR. The changing clinical spectrum of thromboangiitis obliterans (Buerger’s disease). Circulation. 1990;82:Iv3–8.
   PubMed Web of Science ®Google Scholar
• Rivera-Chavarría IJ, Brenes-Gutiérrez JD. Thromboangiitis obliterans (Buerger’s disease). Ann Med Surg. 2016;7:79–82. doi:10.1016/j.amsu.2016.03.028
   PubMed Web of Science ®Google Scholar
• Papa MZ, Rabi I, Adar R. A point scoring system for the clinical diagnosis of Buerger’s disease. Eur J Vasc Endovasc Surg. 1996;11(3):335–339. doi:10.1016/s1078-5884(96)80081-5
   PubMed Web of Science ®Google Scholar
• Swigris JJ, Olin JW, Mekhail NA. Implantable spinal cord stimulator to treat the ischemic manifestations of thromboangiitis obliterans (Buerger’s disease). J Vasc Surg. 1999;29(5):928–935. doi:10.1016/s0741-5214(99)70221-1
   PubMed Web of Science ®Google Scholar
• Dargon PT, Landry GJ. Buerger’s disease. Ann Vasc Surg. 2012;26(6):871–880. doi:10.1016/j.avsg.2011.11.005
   PubMed Web of Science ®Google Scholar
• Eichhorn J, Sima D, Lindschau C, et al. Antiendothelial cell antibodies in thromboangiitis obliterans. Am J Med Sci. 1998;315(1):17–23. doi:10.1097/00000441-199801000-00004
   PubMed Web of Science ®Google Scholar
• Ketha SS, Cooper LT. The role of autoimmunity in thromboangiitis obliterans (Buerger’s disease). Ann N Y Acad Sci. 2013;1285(1):15–25. doi:10.1111/nyas.12048
   PubMedGoogle Scholar
• Lee T, Seo JW, Sumpio BE, Kim SJ. Immunobiologic analysis of arterial tissue in Buerger’s disease. Eur J Vasc Endovasc Surg. 2003;25(5):451–457. doi:10.1053/ejvs.2002.1869
   PubMed Web of Science ®Google Scholar
• Olin JW. Thromboangiitis obliterans (Buerger’s disease). N Engl J Med. 2000;343(12):864–869. doi:10.1056/nejm200009213431207
   PubMed Web of Science ®Google Scholar
• Shionoya S. Diagnostic criteria of Buerger’s disease. Int J Cardiol. 1998;66(Suppl 1):S243–245. doi:10.1016/s0167-5273(98)00175-2
   PubMedGoogle Scholar
• Flammer J, Pache M, Resink T. Vasospasm, its role in the pathogenesis of diseases with particular reference to the eye. Prog Retin Eye Res. 2001;20(3):319–349. doi:10.1016/s1350-9462(00)00028-8
   PubMed Web of Science ®Google Scholar
• Matoba S, Tatsumi T, Murohara T, et al. Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia. Am Heart J. 2008;156(5):1010–1018. doi:10.1016/j.ahj.2008.06.025
   PubMed Web of Science ®Google Scholar
• Fadini GP, Agostini C, Avogaro A. Autologous stem cell therapy for peripheral arterial disease meta-analysis and systematic review of the literature. Atherosclerosis. 2010;209(1):10–17. doi:10.1016/j.atherosclerosis.2009.08.033
   PubMed Web of Science ®Google Scholar
• Lee HC, An SG, Lee HW, et al. Safety and effect of adipose tissue-derived stem cell implantation in patients with critical limb ischemia: a pilot study. Circ J. 2012;76(7):1750–1760. doi:10.1253/circj.cj-11-1135
   PubMed Web of Science ®Google Scholar
• Kawamoto A, Katayama M, Handa N, et al. Intramuscular transplantation of G-CSF-mobilized CD34(+) cells in patients with critical limb ischemia: a phase I/IIa, multicenter, single-blinded, dose-escalation clinical trial. Stem Cells. 2009;27(11):2857–2864. doi:10.1002/stem.207
   PubMed Web of Science ®Google Scholar
• Kim SW, Han H, Chae G-T, et al. Successful stem cell therapy using umbilical cord blood-derived multipotent stem cells for Buerger’s disease and ischemic limb disease animal model. Stem Cells. 2006;24(6):1620–1626. doi:10.1634/stemcells.2005-0365
   PubMed Web of Science ®Google Scholar
• Aksu K, Donmez A, Keser G. Inflammation-induced thrombosis: mechanisms, disease associations and management. Curr Pharm Des. 2012;18(11):1478–1493. doi:10.2174/138161212799504731
   PubMed Web of Science ®Google Scholar
• Kajiguchi M, Kondo T, Izawa H, et al. Safety and efficacy of autologous progenitor cell transplantation for therapeutic angiogenesis in patients with critical limb ischemia. Circ J. 2007;71(2):196–201. doi:10.1253/circj.71.196
   PubMed Web of Science ®Google Scholar
• Lawall H, Bramlage P, Amann B. Treatment of peripheral arterial disease using stem and progenitor cell therapy. J Vasc Surg. 2011;53(2):445–453. doi:10.1016/j.jvs.2010.08.060
   PubMed Web of Science ®Google Scholar
• Lie JT. The rise and fall and resurgence of thromboangiitis obliterans (Buerger’s disease). Acta Pathol Jpn. 1989;39(3):153–158. doi:10.1111/j.1440-1827.1989.tb01494.x
   PubMedGoogle Scholar
• Gao J, Huang L, Wang J. Outcomes of Anticoagulant Therapy with Low-Molecular-Weight Heparin (LMWH) and Warfarin for Thromboangiitis Obliterans (TAO). Curr Vasc Pharmacol. 2021;19(6):655–662. doi:10.2174/1570161119666210118125424
   PubMed Web of Science ®Google Scholar
• Wang X-B, Wang M-L, Chu Y-J, et al. Integrated pharmacokinetics and pharmacometabolomics to reveal the synergistic mechanism of a multicomponent Chinese patent medicine, Mailuo Shutong pills against thromboangiitis obliterans. Phytomedicine. 2023;112:154709. doi:10.1016/j.phymed.2023.154709
   PubMed Web of Science ®Google Scholar
• Zou C, Liu L, Huang C, Hu S. Baiying qingmai formulation ameliorates thromboangiitis obliterans by inhibiting HMGB1/RAGE/NF-κB signaling pathways. Front Pharmacol. 2022;13:1018438. doi:10.3389/fphar.2022.1018438
   PubMed Web of Science ®Google Scholar
• Puéchal X, Fiessinger JN, Kahan A, Menkès CJ. Rheumatic manifestations in patients with thromboangiitis obliterans (Buerger’s disease). J Rheumatol. 1999;26(8):1764–1768.
   PubMed Web of Science ®Google Scholar
• Puechal X, Fiessinger JN. Thromboangiitis obliterans or Buerger’s disease: challenges for the rheumatologist. Rheumatology. 2007;46(2):192–199. doi:10.1093/rheumatology/kel388
   PubMed Web of Science ®Google Scholar
• O’Sullivan GJ. The role of interventional radiology in the management of deep venous thrombosis: advanced therapy. Cardiovasc Intervent Radiol. 2011;34(3):445–461. doi:10.1007/s00270-010-9977-9
   PubMed Web of Science ®Google Scholar
• Cacione DG, Do Carmo Novaes F, Moreno DH. Stem cell therapy for treatment of thromboangiitis obliterans (Buerger’s disease). Cochrane Database Syst Rev. 2018;10(10):Cd012794. doi:10.1002/14651858.CD012794.pub2
   PubMedGoogle Scholar
• Yang L, Tang J, Tian Y, et al. The Preliminary Outcome of Laser-Assisted Angioplasty Combined with Endovascular Radiofrequency Ablation for Thromboangiitis Obliterans. Adv Ther. 2021;38(12):5700–5709. doi:10.1007/s12325-021-01945-x
   PubMed Web of Science ®Google Scholar
• Qu L, Wang A, Tang F. The therapy of transverse tibial bone transport and vessel regeneration operation on thromboangiitis obliterans. Zhonghua Yi Xue Za Zhi. 2001;81(10):622–624.
   PubMedGoogle Scholar
• Wang D, Zhang Y, He G, Zhang X, Qin S. Clinical study on treatment of chronic infection of foot and ankle with lower extremity ischemic diseases by tibial transverse transport combined with antibiotic embedded bone cement. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2020;34(8):979–984. doi:10.7507/1002-1892.202003098
   PubMedGoogle Scholar
• Li MD, Wang YF, Yang MW, Hong FF, Yang SL. Risk Factors, Mechanisms and Treatments of Thromboangiitis Obliterans: an Overview of Recent Research. Curr Med Chem. 2020;27(35):6057–6072. doi:10.2174/0929867326666190816233042
   PubMed Web of Science ®Google Scholar
• Joras M, Poredos P, Fras Z. Endothelial dysfunction in Buerger’s disease and its relation to markers of inflammation. Eur J Clin Invest. 2006;36(6):376–382. doi:10.1111/j.1365-2362.2006.01646.x
   PubMed Web of Science ®Google Scholar
• Kim D-H, Ko Y-G, Ahn C-M, et al. Immediate and late outcomes of endovascular therapy for lower extremity arteries in Buerger disease. J Vasc Surg. 2018;67(6):1769–1777. doi:10.1016/j.jvs.2017.09.020
   PubMed Web of Science ®Google Scholar